Trevena, Inc. (TRVN)
USD 1.27
(-0.78%)
USD 1.27
(-0.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -35.28 Million USD | 38.0% |
| 2022 | -55.51 Million USD | -8.57% |
| 2021 | -51.08 Million USD | -76.11% |
| 2020 | -28.65 Million USD | -26.88% |
| 2019 | -25.6 Million USD | 15.94% |
| 2018 | -28.42 Million USD | 58.64% |
| 2017 | -68.12 Million USD | 34.66% |
| 2016 | -101.01 Million USD | -102.06% |
| 2015 | -50.62 Million USD | -2.25% |
| 2014 | -49.71 Million USD | -118.71% |
| 2013 | -22.63 Million USD | -54.0% |
| 2012 | -14.65 Million USD | 1.65% |
| 2011 | -14.94 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -6.41 Million USD | 39.95% |
| 2024 Q1 | -9.79 Million USD | 69.35% |
| 2023 Q2 | -6.19 Million USD | 38.77% |
| 2023 FY | - USD | 38.99% |
| 2023 Q4 | -9.91 Million USD | -19.37% |
| 2023 Q3 | -8.3 Million USD | -34.04% |
| 2023 Q1 | -10.11 Million USD | -8.26% |
| 2022 Q1 | -16.35 Million USD | -16.56% |
| 2022 FY | - USD | -8.57% |
| 2022 Q4 | -9.34 Million USD | 39.59% |
| 2022 Q3 | -15.47 Million USD | -6.35% |
| 2022 Q2 | -14.54 Million USD | 11.05% |
| 2021 FY | - USD | -76.11% |
| 2021 Q2 | -13.91 Million USD | -43.0% |
| 2021 Q4 | -14.03 Million USD | -2.72% |
| 2021 Q1 | -9.73 Million USD | 18.99% |
| 2021 Q3 | -13.66 Million USD | 1.84% |
| 2020 Q4 | -12.01 Million USD | -134.37% |
| 2020 Q1 | -5.57 Million USD | 9.79% |
| 2020 Q2 | -6.08 Million USD | -9.2% |
| 2020 FY | - USD | -26.88% |
| 2020 Q3 | -5.12 Million USD | 15.79% |
| 2019 Q4 | -6.17 Million USD | 24.95% |
| 2019 Q3 | -8.23 Million USD | -97.39% |
| 2019 Q1 | -4.65 Million USD | 10.91% |
| 2019 Q2 | -4.17 Million USD | 10.4% |
| 2019 FY | - USD | 15.94% |
| 2018 Q1 | -8.37 Million USD | 30.44% |
| 2018 FY | - USD | 58.64% |
| 2018 Q4 | -5.22 Million USD | -36.28% |
| 2018 Q3 | -3.83 Million USD | 49.94% |
| 2018 Q2 | -7.65 Million USD | 8.52% |
| 2017 Q2 | -19.64 Million USD | 6.36% |
| 2017 Q1 | -20.97 Million USD | 41.47% |
| 2017 FY | - USD | 34.66% |
| 2017 Q4 | -12.03 Million USD | 20.07% |
| 2017 Q3 | -15.05 Million USD | 23.33% |
| 2016 Q1 | -17.32 Million USD | -11.81% |
| 2016 Q2 | -18.74 Million USD | -8.23% |
| 2016 FY | - USD | -102.06% |
| 2016 Q4 | -35.83 Million USD | -21.94% |
| 2016 Q3 | -29.38 Million USD | -56.74% |
| 2015 Q3 | -10.42 Million USD | 9.41% |
| 2015 Q1 | -12.79 Million USD | 2.93% |
| 2015 Q2 | -11.5 Million USD | 10.08% |
| 2015 FY | - USD | -2.25% |
| 2015 Q4 | -15.49 Million USD | -48.64% |
| 2014 Q2 | -11.45 Million USD | -22.34% |
| 2014 Q1 | -9.36 Million USD | -13.73% |
| 2014 FY | - USD | -118.71% |
| 2014 Q4 | -13.18 Million USD | 14.93% |
| 2014 Q3 | -15.49 Million USD | -35.26% |
| 2013 Q2 | -4.09 Million USD | -54.84% |
| 2013 Q1 | -2.64 Million USD | 12.9% |
| 2013 Q4 | -8.23 Million USD | -7.41% |
| 2013 FY | - USD | -54.0% |
| 2013 Q3 | -7.66 Million USD | -87.45% |
| 2012 Q4 | -3.03 Million USD | 16.76% |
| 2012 Q3 | -3.64 Million USD | 0.0% |
| 2012 FY | - USD | 1.65% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -7789.254% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -19.596% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 69.06% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -123.894% |
| Better Therapeutics, Inc. | -38.26 Million USD | 7.773% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 7.78% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -97.287% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -4.61% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -5.738% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 66.817% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -3763.059% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -8.639% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 24.424% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -520.858% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -116.475% |
| Molecular Templates, Inc. | 1.43 Million USD | 2567.692% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -154.326% |
| NexImmune, Inc. | -28.16 Million USD | -25.279% |
| Orgenesis Inc. | -60.71 Million USD | 41.882% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 31.204% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -47965.817% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -118.566% |
| Scopus BioPharma Inc. | -11.71 Million USD | -201.268% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 93.464% |
| Statera Biopharma, Inc. | 38.93 Million USD | 190.633% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -412.609% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -62856.95% |
| Vaccinex, Inc. | -19.74 Million USD | -78.692% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -3270.462% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 24.698% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -385.859% |